Federated Hermes Inc. Has $132.81 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Federated Hermes Inc. decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 236,200 shares of the biopharmaceutical company’s stock after selling 9,387 shares during the quarter. Federated Hermes Inc. owned 0.22% of Regeneron Pharmaceuticals worth $132,808,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. Valeo Financial Advisors LLC increased its position in shares of Regeneron Pharmaceuticals by 3.8% in the third quarter. Valeo Financial Advisors LLC now owns 1,866 shares of the biopharmaceutical company’s stock worth $1,049,000 after acquiring an additional 69 shares in the last quarter. J. Safra Sarasin Holding AG boosted its stake in Regeneron Pharmaceuticals by 309.8% in the 3rd quarter. J. Safra Sarasin Holding AG now owns 2,303 shares of the biopharmaceutical company’s stock worth $1,295,000 after purchasing an additional 1,741 shares during the period. Phoenix Financial Ltd. grew its position in Regeneron Pharmaceuticals by 18.2% during the 3rd quarter. Phoenix Financial Ltd. now owns 689 shares of the biopharmaceutical company’s stock worth $387,000 after purchasing an additional 106 shares in the last quarter. General American Investors Co. Inc. raised its stake in Regeneron Pharmaceuticals by 217.6% during the 3rd quarter. General American Investors Co. Inc. now owns 31,362 shares of the biopharmaceutical company’s stock valued at $17,634,000 after purchasing an additional 21,486 shares during the period. Finally, Compass Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $2,043,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bonnie L. Bassler sold 1,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total value of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 7.02% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently weighed in on REGN. Wall Street Zen upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Bank of America raised Regeneron Pharmaceuticals from an “underperform” rating to a “buy” rating and lifted their target price for the company from $627.00 to $860.00 in a research note on Wednesday, January 7th. Evercore ISI increased their price target on shares of Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the stock an “outperform” rating in a research report on Thursday, January 22nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, December 29th. Finally, Royal Bank Of Canada increased their target price on shares of Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $784.77.

Regeneron Pharmaceuticals Price Performance

Shares of REGN opened at $771.25 on Wednesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.33 and a current ratio of 4.06. The firm has a market cap of $81.06 billion, a PE ratio of 18.47, a PEG ratio of 1.99 and a beta of 0.39. The firm’s 50 day moving average price is $757.47 and its 200 day moving average price is $647.23. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the business posted $12.46 EPS. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.